Is hepatitis B virus reactivation a risk factor in the development of posttransplant lymphoproliferative disorder following liver transplantation?

Chinese Medical Journal

Volumn 121, Issue 13, 2008, Pages 1237-1240

  Luo, Yi ^a   Zhang, Ai Bin ^a   Huang, He ^a   Zheng, Shu Sen ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hepatitis B virus; Liver transplantation; Lymphoma; Posttransplant lymphoproliferative disorder

Indexed keywords

ADEFOVIR DIPIVOXIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFATUMUMAB; PREDNISONE; STEROID; TACROLIMUS; VINCRISTINE; VIRUS DNA;

ACUTE GRAFT REJECTION; ADULT; ANTIGEN DETECTION; ARTICLE; B CELL LYMPHOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION RISK; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; VIRUS REACTIVATION; B LYMPHOCYTE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; VIRUS ACTIVATION;

B-LYMPHOCYTES; HEPATITIS B; HUMANS; LIVER TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RISK FACTORS; VIRUS ACTIVATION;

EID: 50549092287     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200807010-00017     Document Type: Article

References (28)

1. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
2. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, et al. Post-transplants lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87: 67-77.
3. Duvoux C, Pageaux GP Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480-patients. Transplantation 2002; 74: 1103-1109.
4. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW Association of the type of induction immunosuppression with post transplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293.
5. Aucejo F, Rofaiel G, Miller C. Who is at risk for posttransplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol 2006; 44: 19-23.
6. Domingo-Doménech E, de Sanjosé S, González-Barca E, Romagosa V, Domingo-Clafós A, Gil-Vernet S, et al. Post-transplant lymphomas: a 20 year epidemiologic, clinical and pathologic study in a single center. Haematologica 2001: 86; 715-721.
7. Jain A, Nalesnik M, Reyes J, Pokharna R, Mazariegos G, Green M, et al. Post-transplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2U02: 236; 429-436.
8. Smets F, Vajro P, Cornu G, Reding R, Otte JB, Sokal E. Indications and results of chemotherapy in children with post-transplant lymphoproliferative disease after liver transplantation. Transplantation 2000: 69; 982-994.
9. Guthery SL, Heubi JF, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, et al. Determination of risk factors for EBV-associated post-transplant lymphoproliferative disorders in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003: 75; 987-993.
10. Opetz G, Henderson R. Incidence ot non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514-1516.
11. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, et al. Pretransplantation assessment of the risks of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
12. Guthery SL, Heubi JE, Bucuvalas JC, Gross TG; Ryckman FC, Alonso MH, et al. Determination of risk factors for EBV-associated post-transplant lymphoproliferative disorders in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 75: 987-993.
13. Norin S,' Kimby E, Ericzon BG, Christensson B, Sander B, Söderdahl G, et al. Post transplant lymphoma-a single-center experience or 500 liver if transplantations. Med Oncol 2004; 21: 273-284.
14. Avolio AW, Agnes S, Barbarino R, Magalini SC, Frongillo F, Pagano L, et al. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series. Transplant Proc 2007; 39: 1956-1960.
15. McLaughlin K, Wajstaub S, Marotta P, Adams P, Grant DR, Wall WJ, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6: 570-574.
16. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post transplant lymphoproliferative disorders in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900.
17. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica 2006; 91: 554-557.
18. Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007; 109: 1360-1364.
19. Kim JH, Bang YJ, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 2002; 93: 471-477.
20. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005; 74: 158-165.
21. Cucuianu A, Patiu M, Duma M, Basarab C, Soritau O, Bojan A, et al. Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients. Br J Haematol 1999; 107: 353-356.
22. Kuniyoshi M, Nakamuta M, Sakai H, Enjoji M, Kinukawa N, Kotoh K, et al. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma. J Gastroenterol Hepatol 2001; 16: 215-219.
23. Ulcickas Yood M, Quesenberry CP Jr, Guo D, Caldwell C, Wells K, Shan J, et al. Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46: 107-112.
24. Heimann R, Lespagnard L, Desmet V. Pathogenic role of hepatitis B virus (HBV). Am J Pathol 1995; 147: 223.
25. Rui L, Goodnow CC. Lymphoma and the control of B cell growth and differentiation. Curr Mol Med 2006; 6: 291-308.
26. Huang CF, Lin SS, Ho YC, Chen FL, Yang CC. The immune response induced by hepatitis B virus principal antigens. Cell Mol Immunol 2006; 3: 97-116.
27. Dewantoro O, Gani RA, Akbar N. Hepatocarcinogenesis in viral hepatitis B infection: the role of HBx and p53. Acta Med Indones 2006; 38: 154-159.
28. Leung N. HBV and liver cancer. Med J Malaysia 2005; 60: 63-68.